靶向新诊断4级星形细胞瘤的EGFR双特异性抗体武装T细胞联合放疗和替莫唑胺的I期研究
本I期研究采用3+3剂量递增设计,评估静脉输注抗CD3×抗EGFR双特异性抗体武装T细胞(EGFR BATs)联合放疗和替莫唑胺治疗新诊断4级星形细胞瘤的安全性和可行性。最高可行剂量为80×10^9 EGFR BATs,7例患者中未出现剂量限制性毒性,因T细胞扩增有限无法继续递增剂量;3例MGMT启动子未甲基化肿瘤患者接受每周8次EGFR BATs单药输注也未出现剂量限制性毒性。EGFR BATs输注可诱导外周血单核细胞抗肿瘤细胞毒活性(p<0.03)、NK细胞活性(p<0.002)及血清IFN-γ(p<0.03)、IL-2(p<0.007)、GM-CSF(p<0.009)升高。
要点
- 最高可行剂量为80×10^9 EGFR BATs,7例患者中未出现剂量限制性毒性。
- 因T细胞扩增有限,未能继续递增剂量。
- 3例MGMT未甲基化肿瘤患者接受8次每周EGFR BATs单药输注,未出现剂量限制性毒性。
核心结论
- 以最高可行剂量80×10^9 EGFR BATs联合或不联合替莫唑胺靶向治疗4级星形细胞瘤是安全的,并诱导了显著的抗肿瘤特异性免疫反应。
- 这些结果支持进一步开展临床试验,以检验该过继细胞疗法在MGMT未甲基化胶质母细胞瘤患者中的疗效。
研究设计与样本
- 本I期研究采用3+3剂量递增设计,测试静脉输注EGFR BATs联合放疗和替莫唑胺在新诊断4级星形细胞瘤患者中的安全性和可行性。
- 在确定可行剂量后,扩展队列纳入MGMT启动子未甲基化肿瘤患者,接受每周EGFR BATs治疗而不联合替莫唑胺。
主要发现
- 最高可行剂量为80×10^9 EGFR BATs,7例患者中未出现剂量限制性毒性。
- 因T细胞扩增有限,无法继续递增剂量。
- 额外队列3例MGMT未甲基化肿瘤患者接受8次每周EGFR BATs单药输注,未出现剂量限制性毒性。
- EGFR BATs输注诱导外周血单核细胞对胶质瘤特异性抗肿瘤细胞毒活性升高(p<0.03),NK细胞活性升高(p<0.002)。
- EGFR BATs输注诱导血清IFN-γ浓度升高(p<0.03)、IL-2浓度升高(p<0.007)、GM-CSF浓度升高(p<0.009)。
关键数值与推荐
- 最高可行剂量为80×10^9 EGFR BATs。
- 7例患者中未出现剂量限制性毒性。
- 3例MGMT未甲基化肿瘤患者接受8次每周EGFR BATs单药输注,未出现剂量限制性毒性。
- 外周血单核细胞抗胶质瘤细胞毒活性升高p<0.03,NK细胞活性升高p<0.002。
- 血清IFN-γ升高p<0.03,IL-2升高p<0.007,GM-CSF升高p<0.009。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因T细胞扩增有限,无法继续递增剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to determine the safety, feasibility, and immunologic responses of treating grade 4 astrocytomas with multiple infusions of anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed T cells (EGFR BATs) in combination with radiation and chemotherapy. METHODS: This phase I study used a 3 + 3 dose escalation design to test the safety and feasibility of intravenously infused EGFR BATs in combination with radiation and temozolomide (TMZ) in patients with newly diagnosed grade 4 astrocytomas (AG4). After finding the feasible dose, an expansion cohort with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) tumors received weekly EGFR BATs without TMZ. RESULTS: The highest feasible dose was 80 × 109 EGFR BATs without dose-limiting toxicities (DLTs) in seven patients. We could not escalate the dose because of the limited T-cell expansion. There were no DLTs in the additional cohort of three patients with unmethylated MGMT tumors who received eight weekly infusions of EGFR BATs without TMZ. EGFR BATs infusions induced increases in glioma specific anti-tumor cytotoxicity by peripheral blood mononuclear cells (p < 0.03) and NK cell activity (p < 0.002) ex vivo, and increased serum concentrations of IFN-γ (p < 0.03), IL-2 (p < 0.007), and GM-CSF (p < 0.009). CONCLUSION: Targeting AG4 with EGFR BATs at the maximum feasible dose of 80 × 109, with or without TMZ was safe and induced significant anti-tumor-specific immune responses. These results support further clinical trials to examine the efficacy of this adoptive cell therapy in patients with MGMT-unmethylated GBM. CLINICALTRIALS: gov Identifier: NCT03344250.
引用
- Fadul CE, Thakur A, Kim J, et al. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide. J Neurooncol. 2024. PMID: 38263486. doi:10.1007/s11060-024-04564-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。